1. MENS shares fluctuated post lock-up expiry, increasing trading volume. 2. Ongoing discussions with investment funds aim to boost share ownership. 3. Company remains compliant with SEC regulations; no new material developments reported. 4. Jyong Biotech completed multiple clinical trials and signed LOIs with pharmaceuticals. 5. The company seeks to expand its global presence in medicinal plants.
FAQ
Why Bullish?
The increase in trading volume often precedes positive market trends. Historical precedents suggest significant interest from investors correlates to share price growth.
How important is it?
The article discusses factors likely to influence MENS's trading dynamics, including investment interest and successful trials.
Why Short Term?
Immediate interest from investors can quickly influence stock price fluctuations. Recently completed clinical trials add to positive sentiment short-term.
Jyong Biotech Ltd. Addresses Recent Share Price Fluctuations
New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) – Jyong Biotech Ltd. (Nasdaq: MENS) has announced that it is closely monitoring the fluctuations in its share price and the notable increase in trading volume on the Nasdaq Stock Exchange. These changes follow the recent expiration of the lock-up period for its shares this month. The company is currently engaged in discussions with investment funds interested in acquiring its ordinary shares.
Compliance and Transparency
Jyong Biotech reassures investors that it complies fully with its continuous disclosure obligations under SEC regulations. The company has stated that there is no material, unpublished price-sensitive information or corporate developments that would explain the recent trading behavior.
The company emphasized that its research, development, and operational activities remain robust, with financial results aligning with disclosures found in its latest public filings, including the Current Report on Form 6-K.
Market Influences on Share Price
The fluctuations in Jyong Biotech's share price, represented by the ticker MENS, can be attributed to a variety of factors beyond its control. These include general market conditions, sector-specific developments, and inherent supply and demand dynamics.
Jyong Biotech is committed to keeping its shareholders informed about all key developments, in line with applicable laws and regulations.
Clinical Trials and Future Development
The company has successfully completed four Phase III clinical trials (API-1) in the United States and Taiwan, alongside one Phase II clinical trial conducted in Taiwan. Jyong Biotech plans to advance the development of its novel botanical drugs further, working towards regulatory approvals for its investigational pipeline.
- Holds global multi-country invention patents.
- Secured Letters of Intent (LOIs) with several international pharmaceutical companies.
- Aims to expand its global footprint and deliver innovative botanical drugs.
Company Overview
Founded in 2002, Jyong Biotech Ltd. is a pioneering biotechnology firm headquartered in Taiwan. The company specializes in developing and commercializing innovative plant-derived drugs, focusing on treatments for urinary system diseases with significant market potentials in the U.S., EU, and Asian markets.
Jyong Biotech has established comprehensive capabilities across all drug development phases, including:
- Early-stage drug discovery and development
- Pharmacology and toxicology
- Clinical trials and regulatory affairs
- Manufacturing and commercialization
Leveraging its proprietary platform, the company is progressing various botanical drug candidates, including its leading candidate BOTRESO®.
Future Outlook and Cautionary Statements
This release contains forward-looking statements regarding plans and future performance. These predictions may differ significantly from actual results due to several risks and uncertainties, including market conditions. Investors are advised to refer to the “Risk Factors” section of the company’s filings with the SEC available at www.sec.gov.
For further information, please visit Jyong Biotech’s official websites at jyongbio.com and jyongir.com.
Contact Information
For investor relations inquiries, please contact:
Email: ir@jyongbio.com
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214